Entera Bio Ltd. Ordinary Shares (ENTX) Stock Price

ENTXStock

$3.47+76.29%52W

Market Cap$600.80M

P/E—

PEG Ratio—

Div yield—

Beta1.42

ENTX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)133.04%

Price vs S&P 500 (4W)1.86%

VGM Score34.39

Book Value / Share (Quarterly)$0.23

P/TBV (Annual)2.30x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-31.38%

Cash Flow / Share (Quarterly)$-0.20

Price vs S&P 500 (YTD)64.33%

Gross Margin (TTM)4.04%

Net Profit Margin (TTM)-4525.11%

EPS (TTM)$-0.26

10-Day Avg Trading Volume0.39M

EPS Excl Extra (TTM)$-0.26

Revenue Growth (5Y)-35.28%

EPS (Annual)$-0.25

ROI (Annual)-87.31%

Gross Margin (Annual)0.00%

Net Profit Margin (5Y Avg)-9546.37%

Cash / Share (Quarterly)$0.09

ROA (Last FY)-71.53%

Revenue Growth TTM (YoY)-76.80%

EBITD / Share (TTM)$-0.26

ROE (5Y Avg)-91.24%

Operating Margin (TTM)-4522.87%

Cash Flow / Share (Annual)$-0.16

P/B Ratio46.17x

P/B Ratio (Quarterly)4.84x

Net Income / Employee (Annual)$-571,900

EV / Revenue (TTM)2194.25x

Net Interest Coverage (TTM)-407.33x

ROA (TTM)-74.79%

EPS Incl Extra (Annual)$-0.25

Current Ratio (Annual)6.94x

Quick Ratio (Quarterly)7.73x

3-Month Avg Trading Volume1.85M

52-Week Price Return76.29%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.88

P/S Ratio (Annual)11748.91x

Asset Turnover (Annual)0.00x

52-Week High$4.20

Operating Margin (5Y Avg)-9584.75%

EPS Excl Extra (Annual)$-0.25

CapEx CAGR (5Y)16.43%

26-Week Price Return144.29%

Quick Ratio (Annual)6.93x

13-Week Price Return169.29%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)7.93x

Enterprise Value$489.32M

Revenue / Share Growth (5Y)-46.27%

Asset Turnover (TTM)0.02x

Book Value / Share Growth (5Y)-4.47%

Revenue / Employee (Annual)$2,100

Pretax Margin (Annual)-27235.71%

Cash / Share (Annual)$0.15

3-Month Return Std Dev198.26%

Gross Margin (5Y Avg)16.41%

Net Income / Employee (TTM)$-618,900

ROE (Last FY)-87.31%

Net Interest Coverage (Annual)-445.45x

EPS Basic Excl Extra (Annual)$-0.25

Receivables Turnover (TTM)0.67x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.26

Receivables Turnover (Annual)0.67x

ROI (TTM)-87.97%

P/S Ratio (TTM)2212.80x

Pretax Margin (5Y Avg)-9524.31%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.63

Price vs S&P 500 (52W)57.98%

Year-to-Date Return76.29%

5-Day Price Return18.34%

EPS Normalized (Annual)$-0.25

ROA (5Y Avg)-79.03%

Net Profit Margin (Annual)-27235.71%

Month-to-Date Return14.38%

Cash Flow / Share (TTM)$-0.34

EBITD / Share (Annual)$-0.25

Operating Margin (Annual)-27450.00%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-91.24%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.26

P/TBV (Quarterly)5.34x

P/B Ratio (Annual)6.79x

Pretax Margin (TTM)-4518.83%

Book Value / Share (Annual)$0.28

Price vs S&P 500 (13W)166.50%

Beta1.42x

Revenue / Share (TTM)$0.00

ROE (TTM)-87.97%

52-Week Low$0.91

vGradeF

gGradeF

mGradeA

vgmGradeD

ENTX Earnings Surprise History

Q2 25-0.06est. -0.11

Q3 25-0.07est. -0.09

Q4 25-0.06est. -0.09

Q1 26-0.07est. -0.08

Q2 26-0.14est. -0.08

ENTX Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.14

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
ENTXEntera Bio Ltd. Ordinary Shares	F	F	A	$3.47
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23

About Entera Bio Ltd. Ordinary Shares

Entera Bio is a clinical-stage biopharmaceutical company developing orally administered peptide therapeutics for chronic conditions, including osteoporosis and hypoparathyroidism. Its lead candidates are first-in-class mini tablet formulations of synthetic PTH (1-34) with tailored pharmacokinetic profiles, designed to offer patients a more convenient alternative to current injectable therapies.